Bayer wins FDA nod for use of Gadavist in cardiac MRI

2018 12 03 21 20 5022 Bayer Rsna 2018 400

Bayer said it has received approval from the U.S. Food and Drug Administration (FDA) for the use of its Gadavist (gadobutrol) gadolinium-based contrast agent in cardiac MRI applications.

The FDA approval allows for gadobutrol injection during cardiac MRI exams to assess myocardial perfusion and late gadolinium enhancement in adults with known or suspected coronary artery disease, according to Bayer. The decision follows reports of the efficacy of gadobutrol for cardiac MR from two phase III clinical trials.

Page 1 of 610
Next Page